RLAY vs KYMR vs ARVN vs PRAX vs VKTX

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Relay Therapeutics, Inc. (RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +435. 3%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus RLAY's -64. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arvinas, Inc.

(ARVN) is the lower-risk stock at 1. 15β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 54% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 6% for Relay Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Praxis Precision Medicines, Inc.

(PRAX) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAX leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RLAY is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; VKTX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.